Postal Realty Trust, Inc. filed a Form 8-K on September 9, 2026, disclosing that it closed on the acquisition of a 72-property portfolio leased to the United States Postal Service for approximately $27.75 million, effective September 4, 2026.
The Chemours Company filed a Form 8-K with the SEC on September 9, 2026, disclosing that it had posted an investor presentation to its website for use in upcoming meetings with investors, analysts, and other interested parties.
Sysco Corporation filed a Form 8-K with the SEC on September 9, 2026, disclosing that the company reaffirmed its fiscal 2027 guidance, announced a $500 million multi-year AI powered efficiency improvement program, and raised certain mid-term financial algorithm targets.
Independence Realty Trust, Inc. filed a current report on September 9, 2026, disclosing that on September 8, 2026, it entered into an Agreement and Plan of Merger with Centerspace, a North Dakota real estate investment trust, under which each Centerspace share would be converted …
Albertsons Companies, Inc. filed a Form 8-K on September 9, 2026, disclosing the appointment of Margaret Whitman to its Board of Directors as Executive Chair, effective September 8, 2026.
Twenty One Capital, Inc. filed a Form 8-K on September 9, 2026, disclosing the appointment of David J. Goldschmidt to its Board of Directors and Audit Committee, effective September 8, 2026.
D-Wave Quantum Inc. filed a Form 8-K/A (Amendment No. 1) on September 9, 2026, reporting the execution of a Securities Issuance Agreement with the U.S. Department of Commerce and the issuance of common stock in connection with an Other Transaction Agreement providing for an …
Kura Oncology, Inc. filed a Form 8-K on September 9, 2026, disclosing the formation of a wholly owned subsidiary, Caspian Therapeutics, Inc., and the completion of a $50.0 million Series A preferred stock financing for that subsidiary on September 8, 2026.
NovoCure Limited filed a Form 8-K on September 9, 2026, disclosing that director Timothy Scannell retired from the company's Board of Directors effective September 2, 2026.
Tyra Biosciences, Inc. filed an 8-K on September 9, 2026, disclosing initial clinical results from its SURF302 Phase 2 study of oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, along with updates from two additional studies.